EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pitfalls in 2HG Detection With TE‐Optimized MRS at 3T

Seyma Alcicek, Dunja Simicic, Lindsay Blair, Max Saint-Germain, Helge J Zöllner, Christopher W Davies-Jenkins, Matthias Holdhoff, John Laterra, Chetan Bettegowda, Karisa C Schreck, Doris D Lin, Peter B Barker und 2 weitere

Journal of Neuroimaging · 2026

DOI: 10.1111/jon.70146 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuroimaging, 2026. Verfasst von Seyma Alcicek und 13 weiteren Autor:innen. Beteiligte Einrichtung: Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Brain Neoplasms, Glutarates, Glioma. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mildred-Scheel Career Center (Deutsche Krebshilfe), NIH HHS, NIBIB NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose In vivo MRS of 2‐hydroxyglutarate (2HG) may provide diagnostic and monitoring biomarkers in isocitrate dehydrogenase (IDH)‐mutated glioma. A previous meta‐analysis has shown good diagnostic accuracy of TE‐optimized PRESS for IDH‐mutated glioma, but most studies feature IDH‐wildtype glioma as a comparison. However, when considering newly identified brain lesions that may mimic glioma, full characterization of its diagnostic utility should also consider the accuracy of 2HG measurement in nontumor tissue. Therefore, we tested how well TE‐optimized 2HG levels distinguish between IDH‐mutated glioma and nontumor tissue—here, normal‐appearing brain. We further examined the impact of different spectral modeling strategies (baseline stiffness, macromolecule inclusion, and basis set composition).

Methods

Forty‐eight patients with diagnosed/suspected IDH‐mutated glioma were enrolled. 3T MRS data were acquired from tumor and contralateral nontumor tissue with TE‐optimized PRESS and analyzed with “LCModel” software. ROC analysis evaluated 2HG estimates’ ability to distinguish IDH‐mutated glioma from nontumor tissue. Modeling interactions between 2HG and other metabolites were evaluated to identify reasons for potential false‐positive 2HG detection.

Results

TE‐optimized PRESS distinguished IDH‐mutated glioma from nontumor tissue with lower sensitivity (range 0.76–0.62) and specificity (0.85–0.78) than the literature suggests for IDH‐mutated versus IDH‐wildtype glioma. Strong negative correlations between gamma‐aminobutyric acid (GABA) and 2HG persisted across all modeling strategies and may lead to false‐positive 2HG detection in nontumor tissue. We further present a cautionary example from a patient on a ketogenic diet, showing that ketone body acetone can interfere with 2HG detection.

Conclusions

Spectral overlap with GABA and acetone can lead to false‐positive 2HG detection in nontumor tissue.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsGlutaratesGliomaHumansMagnetic Resonance SpectroscopyFemaleSensitivity and SpecificityIsocitrate DehydrogenaseMaleMiddle AgedReproducibility of ResultsAdultBiomarkers, Tumor

Stichwörter der Autor:innen

D‐2‐hydroxyglutaratebiomarkerisocitrate dehydrogenase mutationmagnetic resonance spectroscopyoncometabolites

Substanzen

Glutaratesalpha-hydroxyglutarateIsocitrate DehydrogenaseBiomarkers, Tumor

Autor:innen und Institutionen

  • Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Institute of Neuroradiology and Cooperative Brain Imaging Center - CoBIC, University Hospital, Frankfurt am Main, Germany.
  • University Cancer Center Frankfurt (UCT), Frankfurt am Main, Germany.
  • German Cancer Research Center (DKFZ), Frankfurt am Main, Germany.
  • Frankfurt Cancer Institute (FCI), Frankfurt am Main, Germany.
  • Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Förderung

  • Mildred-Scheel Career Center (Deutsche Krebshilfe)
  • NIH HHS
  • NIBIB NIH HHS
  • NIA NIH HHS
  • National Institutes of Health

Zitieren

APA

Alcicek, S., Simicic, D., Blair, L., Saint-Germain, M., Zöllner, H. J., Davies-Jenkins, C. W., Holdhoff, M., Laterra, J., Bettegowda, C., Schreck, K. C., Lin, D. D., Barker, P. B., Kamson, D. O., & Oeltzschner, G. (2026). Pitfalls in 2HG Detection With TE‐Optimized MRS at 3T. Journal of Neuroimaging. https://doi.org/10.1111/jon.70146

Vancouver

Alcicek S, Simicic D, Blair L, Saint-Germain M, Zöllner HJ, Davies-Jenkins CW, et al. Pitfalls in 2HG Detection With TE‐Optimized MRS at 3T. Journal of Neuroimaging. 2026. doi:10.1111/jon.70146

BibTeX
@article{Alcicek2026,
  author = {Alcicek, Seyma and Simicic, Dunja and Blair, Lindsay and Saint-Germain, Max and Zöllner, Helge J and Davies-Jenkins, Christopher W and Holdhoff, Matthias and Laterra, John and Bettegowda, Chetan and Schreck, Karisa C and Lin, Doris D and Barker, Peter B and Kamson, David O and Oeltzschner, Georg},
  title = {Pitfalls in 2HG Detection With TE‐Optimized MRS at 3T},
  journal = {Journal of Neuroimaging},
  year = {2026},
  doi = {10.1111/jon.70146}
}
Kostenlos starten →